Home >> Pharmaceuticals >> Food & Beverage >>

Ageing - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 49 | Code: MRS - 18282

Ageing - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Ageing - Pipeline Review, H1 2015’, provides an overview of the Ageing’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ageing
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ageing and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ageing products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ageing pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ageing
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ageing pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ageing Overview 7
Therapeutics Development 8
Pipeline Products for Ageing - Overview 8
Pipeline Products for Ageing - Comparative Analysis 9
Ageing - Therapeutics under Development by Companies 10
Ageing - Therapeutics under Investigation by Universities/Institutes 11
Ageing - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Ageing - Products under Development by Companies 14
Ageing - Products under Investigation by Universities/Institutes 15
Ageing - Companies Involved in Therapeutics Development 16
Bioo Therapeutics 16
Neuralstem, Inc. 17
RepliCel Life Sciences, Inc. 18
RXi Pharmaceuticals Corporation 19
Ageing - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BIOO-4 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BIOO-7 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs for Ageing - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
metformin + sirolimus - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MG-29 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MMP-26051 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MMP-26052 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NSI-189 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RCS-01 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
sirolimus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule for Alzheimer's Disease and Ageing - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TM-5441 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Ageing - Recent Pipeline Updates 43
Ageing - Dormant Projects 46
Ageing - Product Development Milestones 47
Featured News & Press Releases 47
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Ageing, H1 2015 8
Number of Products under Development for Ageing - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Ageing - Pipeline by Bioo Therapeutics, H1 2015 16
Ageing - Pipeline by Neuralstem, Inc., H1 2015 17
Ageing - Pipeline by RepliCel Life Sciences, Inc., H1 2015 18
Ageing - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Assessment by Combination Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Ageing Therapeutics - Recent Pipeline Updates, H1 2015 43
Ageing - Dormant Projects, H1 2015 46

List of Figures
Number of Products under Development for Ageing, H1 2015 8
Number of Products under Development for Ageing - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing